Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying neuroblastoma, a type of cancer that most often affects children and develops from immature nerve cells. The study will compare two different imaging methods used to detect this disease. The first method uses a substance called [18F]meta-fluorobenzylguanidine (also known as [18F]mFBG) in a type of scan called PET-CT. The second method uses iodine (123I) iobenguane (also known as [123I]mIBG) in a scan called SPECT-CT. Both substances are injected into the body and help to highlight areas where the cancer might be present.
The purpose of this study is to compare how well these two imaging methods can detect cancer in the bones of patients with neuroblastoma. Participants in the study will undergo both types of scans, and the results will be compared to see which method is more effective at finding cancerous lesions. The study will also look at other factors, such as the amount of radiation absorbed by the body during each type of scan and the number of cancerous areas detected.
This study is expected to take place over several years, with the goal of improving the way neuroblastoma is diagnosed and monitored. By comparing these two imaging methods, researchers hope to find the most accurate and safe way to detect this type of cancer, which could lead to better treatment outcomes for patients in the future.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
4 criteria
4 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a type of imaging agent used in PET-CT scans. It helps doctors see detailed images of the body, particularly to detect skeletal lesions in patients with neuroblastoma. This imaging agent is being studied to see if it provides better diagnostic information compared to other methods.
is another imaging agent used in SPECT-CT scans. It is commonly used to detect neuroblastoma, a type of cancer that often affects children. This agent helps in visualizing the spread of cancer in the body, especially in the bones. The study aims to compare its effectiveness with the newer agent, [18F]mFBG.
This medication is administered through a PET-CT scan, a type of imaging test. It is currently being studied in clinical trials to evaluate its effectiveness in diagnosing neuroblastoma, a type of cancer that occurs in children. The main therapeutic indication is to detect skeletal lesions associated with neuroblastoma. At the molecular level, [18F]mFBG works by binding to certain receptors on cancer cells, allowing them to be visualized during the PET-CT scan. It is classified as a radiopharmaceutical used for diagnostic imaging.
This medication is administered through a SPECT-CT scan, another form of imaging test. It is a well-established method in medical literature for diagnosing neuroblastoma. The primary therapeutic indication is to identify and assess the extent of neuroblastoma in the body. The mechanism of action involves the uptake of the radioactive iodine-labeled compound by neuroblastoma cells, which can then be detected by the SPECT-CT scan. It is also classified as a radiopharmaceutical used for diagnostic imaging.
Other trials in this disease – keep exploring while you decide
Denmark
Spain
The Netherlands
Germany
Austria
Italysourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.
